Giorgio Parmiani


Ontology type: schema:Person     


Person Info

NAME

Giorgio

SURNAME

Parmiani

Publications in SciGraph latest 50 shown

  • 2018-12 Immune landscape and in vivo immunogenicity of NY-ESO-1 tumor antigen in advanced neuroblastoma patients in BMC CANCER
  • 2016-11 “Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2016-01 “Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-12 Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2015-12 Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2015 Vaccination in Human Solid Tumors: Recent Progress in the Clinical Arena in CANCER IMMUNOLOGY
  • 2015 Resistance of Cancer Stem Cells to Cell-Mediated Immune Responses in RESISTANCE OF CANCER CELLS TO CTL-MEDIATED IMMUNOTHERAPY
  • 2015-01 Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2015-01 “Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2014-12 Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme in JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
  • 2013-12 Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2013-11 Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study in JOURNAL FOR IMMUNOTHERAPY OF CANCER
  • 2013-05 Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-09 Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2012-08 Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2011-12 Defining the critical hurdles in cancer immunotherapy in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2011-06 Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7–9, 2010 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2010-12 Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1–3 October 2009 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2010-07 Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2010-06 Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008 in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2009-07 Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2009-07 Modified peptides in anti-cancer vaccines: are we eventually improving anti-tumour immunity? in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2009-05 TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2009 Tumor-Derived Exosomes as Dendritic Cell Modulators in DENDRITIC CELLS IN CANCER
  • 2008-12 The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2008-09 Limitations of the cancer stem cell theory in CYTOTECHNOLOGY
  • 2008-01 Tumour-released exosomes and their implications in cancer immunity in CELL DEATH & DIFFERENTIATION
  • 2007-12 Low TCR avidity and lack of tumor cell recognition in CD8+ T cells primed with the CEA-analogue CAP1-6D peptide in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2007-04 Vaccination therapy in prostate cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2007-04 International Meeting “Immunotherapy of Cancer: Challenges and Needs” in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2006-08 A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2006-06 Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma in ONCOGENE
  • 2005-12 A Merging Duo in Melanoma Formation in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2005-03 A listing of human tumor antigens recognized by T cells: March 2004 update in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2004-08 BRAF alterations are associated with complex mutational profiles in malignant melanoma in ONCOGENE
  • 2004-03 Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2003-11 Potent Phagocytic Activity Discriminates Metastatic and Primary Human Malignant Melanomas: A Key Role of Ezrin in LABORATORY INVESTIGATION
  • 2002-03 Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2002-03 Comparative assessment of TCRBV diversity in T lymphocytes present in blood, metastatic lesions, and DTH sites of two melanoma patients vaccinated with an IL-7 gene-modified autologous tumor cell vaccine in CANCER GENE THERAPY
  • 2002 Melanoma: The Milan Melanoma Cell Lines in HUMAN CELL CULTURE
  • 2001-09 CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation in BRITISH JOURNAL OF CANCER
  • 2001-07 Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy in CANCER GENE THERAPY
  • 2001-06-01 Gene Therapy in Melanoma in MELANOMA TECHNIQUES AND PROTOCOLS
  • 2001-06 Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2001-03 A listing of human tumor antigens recognized by T cells in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2001 T cell response to tumor antigens and its therapeutic use in cancer patients in PROGRESS IN BASIC AND CLINICAL IMMUNOLOGY
  • 2000-07 Human Melanocytes and Melanomas Express Novel mRNA Isoforms of the Tyrosinase-Related Protein-2/DOPAchrome Tautomerase Gene: Molecular and Functional Characterization in JOURNAL OF INVESTIGATIVE DERMATOLOGY
  • 2000-06 Conference on cancer vaccines in CANCER IMMUNOLOGY, IMMUNOTHERAPY
  • 2000-01 Type I consensus interferon (CIFN) gene transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha in GENE THERAPY
  • 1999-05 Cytotoxic T lymphocyte response against non-immunoselected tumor antigens predicts the outcome of gene therapy with IL-12-transduced tumor cell vaccine in GENE THERAPY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.411477.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.208078.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.18887.3e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416651.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410396.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.414038.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.486806.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417893.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.15496.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412530.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476288.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416153.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.21925.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7605.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419546.b", 
            "type": "Organization"
          }
        ], 
        "familyName": "Parmiani", 
        "givenName": "Giorgio", 
        "id": "sg:person.0700363627.04", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0002-2929-0254"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700363627.04", 
          "https://orcid.org/0000-0002-2929-0254"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:06", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_799.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0700363627.04'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0700363627.04'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0700363627.04'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0700363627.04'


     

    This table displays all metadata directly associated to this object as RDF triples.

    51 TRIPLES      11 PREDICATES      28 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.0700363627.04 schema:affiliation Neff0f436cf31410dbe423a560ef6633a
    2 https://www.grid.ac/institutes/grid.15496.3f
    3 https://www.grid.ac/institutes/grid.18887.3e
    4 https://www.grid.ac/institutes/grid.208078.5
    5 https://www.grid.ac/institutes/grid.21925.3d
    6 https://www.grid.ac/institutes/grid.240145.6
    7 https://www.grid.ac/institutes/grid.410396.9
    8 https://www.grid.ac/institutes/grid.412530.1
    9 https://www.grid.ac/institutes/grid.414038.a
    10 https://www.grid.ac/institutes/grid.416153.4
    11 https://www.grid.ac/institutes/grid.416651.1
    12 https://www.grid.ac/institutes/grid.417893.0
    13 https://www.grid.ac/institutes/grid.419546.b
    14 https://www.grid.ac/institutes/grid.476288.7
    15 https://www.grid.ac/institutes/grid.486806.4
    16 https://www.grid.ac/institutes/grid.7605.4
    17 schema:familyName Parmiani
    18 schema:givenName Giorgio
    19 schema:identifier Ne57d2e1b17fa4af586b0b950ea160d03
    20 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700363627.04
    21 https://orcid.org/0000-0002-2929-0254
    22 schema:sdDatePublished 2019-03-07T15:06
    23 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    24 schema:sdPublisher N3e252c8389a64270843ffa23cd776f74
    25 sgo:license sg:explorer/license/
    26 sgo:sdDataset persons
    27 rdf:type schema:Person
    28 N3e252c8389a64270843ffa23cd776f74 schema:name Springer Nature - SN SciGraph project
    29 rdf:type schema:Organization
    30 Ne57d2e1b17fa4af586b0b950ea160d03 schema:name orcid_id
    31 schema:value 0000-0002-2929-0254
    32 rdf:type schema:PropertyValue
    33 Neff0f436cf31410dbe423a560ef6633a schema:affiliation https://www.grid.ac/institutes/grid.411477.0
    34 sgo:isCurrent true
    35 rdf:type schema:OrganizationRole
    36 https://www.grid.ac/institutes/grid.15496.3f schema:Organization
    37 https://www.grid.ac/institutes/grid.18887.3e schema:Organization
    38 https://www.grid.ac/institutes/grid.208078.5 schema:Organization
    39 https://www.grid.ac/institutes/grid.21925.3d schema:Organization
    40 https://www.grid.ac/institutes/grid.240145.6 schema:Organization
    41 https://www.grid.ac/institutes/grid.410396.9 schema:Organization
    42 https://www.grid.ac/institutes/grid.411477.0 schema:Organization
    43 https://www.grid.ac/institutes/grid.412530.1 schema:Organization
    44 https://www.grid.ac/institutes/grid.414038.a schema:Organization
    45 https://www.grid.ac/institutes/grid.416153.4 schema:Organization
    46 https://www.grid.ac/institutes/grid.416651.1 schema:Organization
    47 https://www.grid.ac/institutes/grid.417893.0 schema:Organization
    48 https://www.grid.ac/institutes/grid.419546.b schema:Organization
    49 https://www.grid.ac/institutes/grid.476288.7 schema:Organization
    50 https://www.grid.ac/institutes/grid.486806.4 schema:Organization
    51 https://www.grid.ac/institutes/grid.7605.4 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...